A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

StatusRecruiting

PhasePhase 2

SponsorMerck Sharp & Dohme LLC

Started2025-09-26

View on ClinicalTrials.gov ↗

Amendment history

2026-09-11

Study Status, Contacts/Locations v35

Study sitesdetails revised at 1 of 105 sites

2026-09-05

Study Status, Contacts/Locations v34

Study sites104→105

2026-08-27

Study Status, Contacts/Locations v33

Study sitesdetails revised at 3 of 104 sites

2026-08-20

Study Status v32

Re-verified, no change to tracked fields

2026-07-24

Study Status, Contacts/Locations v31

Study sitesdetails revised at 1 of 104 sites

Show 7 earlier versions

2026-07-17

Study Status, Contacts/Locations v30

Study sitesdetails revised at 1 of 104 sites

2026-07-10

Study Status, Contacts/Locations v29

Study sites102→104

2026-06-25

Study Status, Contacts/Locations v28

Study sites101→102

2026-06-18

Study Status, Contacts/Locations v27

Study sites100→101

2026-06-11

Study Status, Contacts/Locations v26

Study sitesdetails revised at 1 of 100 sites

2026-05-28

Study Status, Contacts/Locations v25

Study sites99→100

2026-05-21

Study Status, Contacts/Locations v24

Study sites98→99

2026-05-08

Study Status, Contacts/Locations v23

Trial sites expanded: 95 → 98 locations

2026-04-16

Study Status, Contacts/Locations v22

Trial sites expanded: 89 → 95 locations

2026-04-02

Study Status, Contacts/Locations v21

Study sites88→89

2026-03-25

Study Status, Contacts/Locations v20

Study sites81→88

2026-02-17

Study Status, Contacts/Locations v19

Study sites73→81

2026-02-10

Study Status, Contacts/Locations v18

Study sites69→73

2026-02-03

Study Status, Contacts/Locations v17

Study sites61→69

2026-01-29

Study Status, Contacts/Locations v16

Study sites58→61

2026-01-23

Study Status, Contacts/Locations v15

Study sites57→58

2026-01-16

Study Status, Contacts/Locations v14

Study sites54→57

2026-01-08

Study Status, Contacts/Locations v13

Study sites53→54

2026-01-02

Study Status, Contacts/Locations v12

Study sites52→53

2025-12-24

Study Status, Contacts/Locations v11

Study sites45→52

2025-12-18

Study Status, Contacts/Locations v10

Study sites37→45

2025-12-12

Study Status, Contacts/Locations v9

Study sites34→37

2025-12-04

Study Status, Contacts/Locations v8

Study sites30→34

2025-11-27

Study Status, Contacts/Locations v7

Study sites28→30

2025-11-20

Study Status, Contacts/Locations v6

Study sites19→28

2025-11-12

Study Status, Contacts/Locations v5

Study sites15→19

2025-11-10

Study Status, Contacts/Locations v4

Study sites14→15

2025-10-30

Study Status, Contacts/Locations v3

Study sites3→14

2025-10-14

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-09-18→confirmed 2025-09-26

Study sites0→3

2025-08-26

Study Status, Study Description, Arms and Interventions v1

Study description+181 characters

This study consists of a 16-week Placebo-controlled Period and a 124-week Long-term Extension (LTE), which is composed of a 40-week Main Extension and an 84-week Optional Extension.

2025-08-14

Original filing

Merck (MSD)

401 trials monitored

See 24 trials at risk

Ankylosing Spondylitis

176 trials monitored

See 6 trials at risk

Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays. This study will help find out if a study medicine called tulisokibart can treat symptoms of r-axSpA. Researchers will look at different doses of tulisokibart. Researchers want to know if at least one of the study doses of tulisokibart works better than a placebo to improve r-axSpA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Trial Details

NCT Number	NCT07133633
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Radiographic Axial Spondyloarthritis
Enrollment	315 participants
Start Date	2025-09-26
Primary Completion	2027-06-15 (estimated)
Study Completion	2030-02-05 (estimated)
Updated on ClinicalTrials.gov	2026-09-28